Overview

RCMG Inc. was founded by Dr. Narimatsu*, a pioneer of establishing various technologies of glycoscience research over 35-years with great success, intellectual properties and know-how. Dr. Angata*, co-founder and CEO of RCMG Inc, has research experience in glycobiology over 25-years.
RCMG’s proprietary technology platform is able to continually create novel biomarkers/in vitro diagnostics (IVDs) to detect specific disease conditions suitable for the diversity of personalized medicine.

Aim of RCMG Inc. is to contribute to human health care by using glycotechnology that we studied and developed. Glycan is the fourth life chain in the biology field, which is our target molecule presenting differences in cells, organs, and individuals.
Current IVD pipeline includes inflammation, infectious disease, and oncology. Since glycosylation of cellular surfaces and secreted proteins reflects conditions of cells in patients, suffering from infections or cancers, glyco-biomarkers for specific diseases would create more accurate biomarkers.
> Project Page